Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

BMS acquires biotech Cormorant

by Lisa M. Jarvis
July 11, 2016 | A version of this story appeared in Volume 94, Issue 28

Further expanding its immuno-oncology portfolio, Bristol-Myers Squibb has acquired Cormorant Pharmaceuticals for up-front and near-term milestone fees of up to $95 million. The deal gives BMS HuMax-IL8, an anti-IL8 antibody that the firm believes can be combined with other immunotherapies to improve responses in cancer patients. The deal brings home an asset that once was controlled by antibody developer Medarex, which BMS acquired in 2009. In 2007, Medarex handed over the rights to HuMax-IL8 to Genmab, which sold the drug candidate to Cormorant in 2012.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.